Navigation Links
OncoSec to Present at the 22nd Annual Oppenheimer Healthcare Conference
Date:12/9/2011

SAN DIEGO, Dec. 9, 2011 /PRNewswire/ -- OncoSec Medical Incorporated (OTCBB: ONCS), a biotechnology company developing advanced-stage OMS ElectroOncology therapies to treat skin cancer and other solid tumor cancers, today announces that Punit Dhillon, President and CEO, will be presenting at the 22nd Annual Oppenheimer Healthcare Conference.

(Logo:  http://photos.prnewswire.com/prnh/20110314/MM64943LOGO)

22nd Annual Oppenheimer Healthcare Conference
The Waldorf Astoria
301 Park Avenue
New York, New York 10022
December 13-14, 2011

OncoSec Presentation
December 13, 2011
3:20 pm ET

A live and archived webcast will be accessible on OncoSec's website www.oncosec.com

To arrange a meeting with management please contact Adam Holdsworth, The Investor Relations Group 212-285-3210 aholdsworth@investorrelationsgroup.com

The Oppenheimer 22nd Annual Healthcare Conference will take place at the historic Waldorf Astoria in New York City. This conference will showcase leading public and private companies specializing in sectors such as biotechnology, medical device, pharmaceutical, diagnostics, healthcare tools, facility and distribution. Attendees will be given opportunities to connect to company leaders through formal presentations, panels and one-on-ones giving insight into current healthcare topics of interest from development of new blockbuster pharmaceutical and biotechnology products to Food and Drug Administration policy, M&A environment, and healthcare reform and impact.

About OncoSec Medical Inc.

OncoSec Medical Incorporated (OTCBB: ONCS) develops novel OMS ElectroOncology therapies that combine its proprietary electroporation delivery technology with a chemotherapeutic or novel DNA-based immunotherapeutics. Targeted local delivery of these agents is designed to achieve selective destruction of cancerous tumors while sparing healthy normal tissue, resulting in improved functional, cosmetic and quality of life outcomes. These therapies have achieved validating safety and efficacy data in early and late stage clinical studies of over 400 cancer patients. OncoSec's clinical programs include three Phase II clinical trials for OMS ElectroImmunotherapy. More information is available at www.oncosec.com. Additional information may also be found at OncoSec's Facebook, Twitter, and LinkedIn sites.

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in OncoSec's filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements which speak only as of the date they are made. OncoSec disclaims any obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE OncoSec Medical Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. OncoSec to Present at 15th Annual Biotech and Specialty Pharmaceuticals Conference
2. OncoSec and Serametrix Collaborate to Identify Potential Biomarkers to Enhance Skin Cancer Immune Therapies
3. OncoSec to Present at Medical Device Investor Forum
4. Device Master File for OncoSec Medical System Completed and Submitted to FDA
5. OncoSec Releases Devices for Use in Clinical Trials
6. Update: OncoSec Announces Positive Results From Head & Neck and Breast Cancer Trials
7. OncoSec Announces Positive Results from Head & Neck and Breast Cancer Trials
8. OncoSec Medical to Attend 6th Annual Fire, Ice and Beyond: The Future of Ablation Therapies Conference
9. OncoSec Medical to Present at Industry and Investor Conferences
10. OncoSec Medical Appoints Engineering Leader
11. OncoSec Medical Announces the Appointment of Dr. Anthony E. Maida, III, to Its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Research and Markets has announced the addition of the ... to 2022" report to their offering. ... financial data derived from varied research sources to present unique ... on the market during the next five years, including a ... markets, regional and country level analysis. The report provides a ...
(Date:6/23/2016)... and INDIANAPOLIS , June ... receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship is any ... scholarship winners, announced today online at www.diabetesscholars.org ... type 1 diabetes stand in the way of academic ... supported the Foundation,s scholarship program since 2012, and continues ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Surgical Procedure Volumes: Global Analysis (United States, ... Australia, Canada)" report to their offering. ... an essential tool for healthcare business planners, provides surgical ... looks at surgery trends with an in-depth analysis of ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. ... magazine’s Code Talker Award, an essay contest in which patients and their families pay ... be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... proud to recognize Dr. Barry M. Weintraub as a prominent plastic surgeon and ... women in the world, and the most handsome men, look naturally attractive. Plastic ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital Partners, LLC (SCP) ... obtaining investment capital for emerging technology companies. SCP has delivered investment events ... in more than a million dollars of capital investment for five companies. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Venture Construction Group (VCG) ... held on June 20th at the Woodmont Country Club at 1201 Rockville Pike, Rockville, ... dedicated to helping service members that have been wounded in battle and their families. ...
(Date:6/24/2016)... ... 24, 2016 , ... Advanced Plastic Surgery Institute ( http://www.advancedplasticsurgeryinstitute.com ... its official Medspa Sponsor. Dr. Josh Olson, a board-certified plastic surgeon, owns the ... Olson says the decision to support the pageant in an official capacity is ...
Breaking Medicine News(10 mins):